New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
17:19 EDTJNJJ&J: New data shows Invokana reduces blood glucose levels
Janssen Research & Development announced new results from a 104-week Phase 3 clinical study evaluating the long-term effects of INVOKANA, canagliflozin, in patients aged 55 to 80 years with type 2 diabetes inadequately controlled on current antihyperglycemic therapies. The randomized double-blind study showed INVOKANA 100 milligrams, mg ,and 300 mg, compared to placebo, provided greater reductions in blood glucose, A1C, and greater reductions in secondary endpoints of fasting plasma glucose, body weight and systolic blood pressure. In the long-term study, DIA3010, after 104 weeks, levels of A1C, the primary endpoint, were significantly reduced with INVOKANA100 mg and 300 mg, respectively, relative to placebo: -0.49% and -0.60%. A1C, also called hemoglobin A1c, is the percent of red blood cell hemoglobin with glucose attached to it, and is an indicator of average blood glucose over the previous two to three months.3
News For JNJ From The Last 14 Days
Check below for free stories on JNJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 18, 2014
11:41 EDTJNJCubist rises after report sparks takeover interest speculation
Subscribe for More Information
August 12, 2014
09:35 EDTJNJActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GOOG C TSL EXAS BAC DNDN JNJ TSLA
August 8, 2014
09:01 EDTJNJJohnson & Johnson remains undervalued, says Cowen
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use